Drug Profile
Research programme: T lymphocyte immunotherapies - Juno Therapeutics
Alternative Names: CAR T cell products - Juno Therapeutics; CARTs - Juno Therapeutics; Chimeric antigen receptor T lymphocytes - Juno Therapeutics; High-affinity TCR T cells; TCR T cell products - Juno TherapeuticsLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Juno Therapeutics; Peter MacCallum Cancer Centre
- Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics; Memorial Sloan-Kettering Cancer Center; Seattle Childrens Research Institute
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (IV, Infusion)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)